Perrigo Company plc Stock News

Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.

Perrigo Company plc (NYSE: PRGO) reported Q1 net sales were $1.01 billion, a decrease of 6.8% year-on-year, missing the consensus of $1.02 billion. Adjusted diluted EPS fell 25.4% to $0.50, well b

Perrigo (PRGO) delivered earnings and revenue surprises of -10.71% and -0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

You may not have heard of Perrigo, but it's a stellar dividend stock, and one that income investors should make sure to watch. The post Undervalued Perrigo Is A Dividend Stock to Have And to Hold appe

Perrigo - Simplifying To Unlock Appeal

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

DUBLIN, April 19, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that its Board of Directors declared

We believe that Perrigo stock, a healthcare company that provides over-the-counter self-care products, including generic drugs and consumer products, is a good buying opportunity at the present time.

Perrigo's (PRGO) CEO Murray Kessler on Q4 2020 Results - Earnings Call Transcript

Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion.

Perrigo (PRGO) delivered earnings and revenue surprises of -7.92% and -2.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Perrigo Company Plc (NYSE: PRGO) has agreed to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners for $1.55 billion.  The price included a $1.5 billion payment in cash.

Perrigo Co. Plc [ said Monday it has agreed to sell its generic business to Altaris Capital Partners LLC for $1.55 billion, including $1.5 billion in cash. Altaris will assume more than $50 million in

Shares of Perrigo (NYSE:PRGO) rose 0.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 12.26% over the past year to $0.93, which missed the esti

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.